RxDoctor Payments Data

Bethany Fees

Nurse Practitioner · Birmingham, ALNPI 1609257336

Payments from drug & device makers

$1,759in general payments, 2019–2025

Across 16 payments — averaging $109.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$1K
  • AbbVie$144
  • GSK$104
  • Bayer$84
  • E.r. Squibb & Sons, L.L.C.$62
  • AstraZeneca$37
  • plus $36 from 2 others

What the payments were for

  • Consulting fees$52030%
  • Speaking & faculty fees$77044%
  • Food & beverage$44725%
  • Education$221%

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Seagen Inc.5$1,290
AbbVie2$144
GSK1$104
Bayer1$84
E.r. Squibb & Sons, L.L.C.3$62
AstraZeneca2$37
Eisai Inc.1$22
Merck1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,759 in reported general payments places this provider in the 75th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$17,005
Medicare patients
125
Services billed
332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib44$703,954
MekinistTrametinib Dimethyl Sulfoxide13$154,660
EliquisApixaban19$11,519
XareltoRivaroxaban14$7,578
PremarinEstrogens, Conjugated17$5,158
Estradiol28$1,301
Prochlorperazine Maleate72$798
Letrozole24$749
Ondansetron Hcl80$675
Duloxetine Hcl32$649
Megestrol Acetate13$468
Dexamethasone14$270
Nystatin13$255
Promethazine Hcl15$243
Fluconazole37$241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$37$703,95444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →